Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence

Journal of Clinical Virology

Volumn 60, Issue 3, 2014, Pages 257-263

  Carozzi, Francesca ^a   De Marco, Laura ^b   Gillio Tos, Anna ^b   Del Mistro, Annarosa ^c   Girlando, Salvatore ^d   Baboci, Lorena ^c   Trevisan, Morena ^b   Burroni, Elena ^a   Grasso, Stefano ^f   Rossi, Paolo Giorgi ^e   Ronco, Guglielmo ^f   Segnan, N ^g   Rizzolo, R ^g   Giubilato, P ^g   Ghiringhello, B ^h   Sapino, A ^b   Accinelli, M G ^b   Maina, G ^h   Pasero, L ^h   Dalla Palma, Trento P ⁱ   Polla, E ⁱ   Frayle Salamanca, Veneto H ^c   Trevisan, R ^c   Zorzi, M ^c   Fedato, C ^c   Baracco, S ^c   Insacco, E ^j   Minucci, D ^j   Matteucci, M ^j   Onnis, G L ^k   Colombari, R ^l   Manfredi, Emilia Romagna M ^m   Casadei, G P ⁿ   Pierotti, P ⁿ   Collina, G ^o   Schincaglia, P ^p   Ser afini, M ^p   Vitali, M ^p   Aldi, M ^q   Folicaldi, S ^q   Nannini, R ^q   Galanti, G ^q   De Lillo, M ^q   Naldoni, C ^r   Confortini, Florence M ^s   Iossa, A ^s   Sani, C ^s   Ciatto, S ^s   Cariaggi, M P ^s   Cecchini, S ^s   Zappa, M ^s   Taddei, G L ^t   Brezzi, Lazio S ^u   Raggi, P ^u   Gomes, E ^u   Pelle grini, A ^v   Schiboni, M L ^v   Borgia, P ^w   Chini, F ^w   more..

^a ISPO Cancer Prevention and Research Institute   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d SANTA CHIARA HOSPITAL   (Italy)

^e PATHOLOGY UNIT   (Italy)

^f Centre for Cancer Prevention   (Italy)

^g CPO Piemonte   (Italy)

^h OIRM S Anna   (Italy)

ⁱ Azienda per i Servizi Sanitari N 2 Isontina   (Italy)

^j Unit of Gynaecology   (Italy)

^k UNIVERSITY OF PADOVA   (Italy)

^l Ospedale di San Bonifacio   (Italy)

^m Azienda USL di Bologna   (Italy)

ⁿ MAGGIORE HOSPITAL   (Italy)

^o BELLARIA HOSPITAL   (Italy)

^p CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^q AUSL   (Italy)

^r Centro di Riferimento Screening   (Italy)

^s ISPO   (Italy)

^t UNIVERSITY OF FLORENCE   (Italy)

^u Local Health Unit   (Italy)

^v SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^w Department of Epidemiology   (Italy)

more..

Author keywords

Genotyping; High risk HPV; Human papillomavirus; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGE; ARTICLE; CANCER SCREENING; CROSS PROTECTION; FEMALE; GENETIC VARIABILITY; GENOTYPE; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; MAJOR CLINICAL STUDY; MIXED INFECTION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SPECIES DISTRIBUTION; URBAN AREA; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION; WART VIRUS; ALPHAPAPILLOMAVIRUS; GENETICS; HEALTH SURVEY; IMMUNOLOGY; ITALY; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX; VIROLOGY;

ADULT; ALPHAPAPILLOMAVIRUS; CERVIX UTERI; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; ITALY; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POPULATION SURVEILLANCE; PREVALENCE; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84902107051     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.04.009     Document Type: Article

References (36)

1. Schiller J.T., Castellsagué X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30S:F123-F138.
2. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255.
3. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmerón J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369:2161-2170.
4. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16 and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.
5. Wheeler C.M., Castellsagué X., Garland S.M., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13(Jan):100-110.
6. Sankaranarayanan R., Nene B.M., Shastri S.S., Jayant K., Muwonge R., Budukh A.M., et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009, 360:1385-1394.
7. Ronco G., Dillner J., Elfström K.M., Tunesi S., Snijders P.J., Arbyn M., et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014, 383(9916):524-532.
8. Naucler P., Ryd W., Törnberg S., Strand A., Wadell G., Elfgren K., et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009, 101:88-99.
9. Rijkaart D.C., Berkhof J., Rozendaal L., van Kemenade F.J., Bulkmans N.W., Heideman D.A., et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012, 13:78-88.
10. Clifford G., Franceschi F., Diaz M., Munoz N., Villa L.L. Chapter 3: HPV distribution in women with and without cervical neoplastic diseases. Vaccine 2006, 24S3. S3/26-34.
11. de Sanjosé S., Diaz M., Castellaguè X., Clifford G., Bruni L., Munoz N., et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta analysis. Lancet Infect Dis 2007, 7:453-460.
12. Franceschi S., Herrero R., Clifford G., Snijders P.J.F., Arslan A., Anh P.T.H., et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006, 119:2677-2680.
13. Clifford G., Gallus S., Herrero R., Muñoz N., Snijders P.J.F., Vaccarella S., et al. Worldwide distribution of HPV types in cytologically normal women: pooled analysis of the IARC HPV prevalence surveys. Lancet 2005, 366:991-1000.
14. de Sanjosé S., Quint W.G.V., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1050.
15. Giorgi Rossi P., Ronco G. HPV types in early-onset cervical cancer. Lancet Oncol 2011, 12:117. [letter].
16. Carozzi F.M., Tornesello M.L., Burroni E., Loquercio G., Carillo G., Angeloni C., et al. Prevalence of human papilloma virus types in high-grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol Biomarkers Prev 2010, 19:2389-2390.
17. Sargent A., Bailey A., Almonte M., Turner A., Thomson C., Peto J., et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer 2008, 98:814-820.
18. Ronco G., Giorgi-Rossi P., Carozzi F., Dalla Palma P., Del Mistro A., De Marco L., et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006, 7:547-550.
19. Ronco G., Segnan N., Giorgi-Rossi P., Zappa M., Casadei G.P., Carozzi F., et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006, 98:765-774.
20. Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone to conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008, 100:492-501.
21. Van den Brule A.J., Pol R., Fransen-Daalmeijer N., Schouls L.M., Meijer C.J., Snijders P.J. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002, 40:779-787.
22. Bouvard V.A., Baan R.A., Straif K.A., Grosse Y., Secretan B., El Ghissassi F. A review of human carcinogens - Part B. biological agents. Lancet Oncol 2009, 10:321-322.
23. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
24. Qu W., Jiang G., Cruz Y., Chang C.J., Ho G.Y., Klein R.S., et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. Clin Microbiol 1997, 35:1304-1310.
25. Nobre R.J., de Almeida L.P., Martins T.C. Complete genotyping of mucosal human papillomavirus using a restriction fragment length polymorphism analysis and an original typing algorithm. J Clin Virol 2008, 42:13-21.
26. GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B., de Borba P.C., Naud P.S., Roteli-Martins C.M., De Carvalho N.S., et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374:1975-1985.
27. Gillio-Tos A., De Marco L., Carozzi F., Del Mistro A., Girlando S., Burroni E., et al. Clinical impact of the analytical specificity of Hybrid Capture 2: data from the NTCC study. J Clin Microbiol 2013, 51:2901-2907.
28. Ronco G., Segnan N., Giordano L., Pilutti S., Senore C., Ponti A., et al. Interaction of spontaneous and organised screening for cervical cancer in Turin, Italy. Eur J Cancer 1997, 8:1262-1267.
29. Carozzi F., Ronco G., Gillio-Tos A., De Marco L., Del Mistro A., Girlando S., et al. Concurrent infections with multiple human papillomavirus (HPV) types in the new technologies for cervical cancer (NTCC) screening study. Eur J Cancer 2012, 48:1633-1637.
30. Giorgi Rossi P., Bisanzi S., Paganini I., Di Iasi A., Angeloni C., Scalisi A., et al. Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study. BMC Infect Dis 2010, 10:214.
31. Malagon T., Drolet M., Boily M.C., Franco E.L., Jit M., Brisson J., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:781-789.
32. Wheeler C.M., Hunt W.C., Joste N.E., Key C.R., Quint W.G., Castle P.E. Human papillomavirus genotyping distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009, 101:475-487.
33. de Sanjosè S., Wheeler C.M., Quint W.G.V., Hunt W.C., Joste N.E., Alemany L., et al. Age-specific occurrence of HPV16- and HPV18-related cervical cancer. Cancer Epidemiol Biomarkers Prev 2013, 22:1313-1318.
34. de Sanjosé S. Author's reply. Lancet Oncol 2011, 12:117.
35. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005, 97:1072-1079.
36. Kjær S.K., Frederiksen K., Munk C., Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010, 102:1478-1488.